At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 36 enrolled
Drug / intervention
MT-1186drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I, Randomized, Open-Label, Crossover-Design, Single-Dose Study to Investigate the Safety, Tolerability and Comparative Bioavailability of Oral Edaravone Administered Orally and Via a Nasogastric Tube (NGT) in Healthy Adult Subjects
In Brief
A Phase 1 clinical trial evaluating MT-1186 for Healthy Adult Subjects. Completed, enrolled 36 participants across 1 site.
Detailed Summary
To investigate the comparative bioavailability of edaravone oral suspension administered orally and via a nasogastric tube in healthy adult subjects
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Adult Subjects
CountriesJapan
Collaborators--
Timeline
Phase 1CompletedFinished
20222023202420252026
Enrollment StartFeb 2021
First PostedMar 2021
Primary CompletionApr 2021
Study CompletionApr 2021
TodayJul 2026
First PostedMar 1, 2021
Enrollment StartFeb 26, 2021
Primary CompletionApr 1, 2021
Study CompletionApr 16, 2021
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 5.3 years ago
Interventions
MT-1186drug
Suspension